Overview
AMGN market data
Price History
AMGN price chart · 1M
- O
- 408.25
- H
- 415.18
- L
- 404.83
- C
- 414.67
- Vol
- 89,901.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $408.25
- Previous Close
- $406.16
- Day High
- $415.18
- Day Low
- $404.83
- 52 Week High
- $447.03
- 52 Week Low
- $320.58
- 7 Day Return
- +7.54%
- 30 Day Return
- -5.83%
- 90 Day Return
- +15.70%
- 1 Year Return
- +23.85%
- Daily Notional Volume
- $37.3M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 25.19 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $14.23 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.45 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.2% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 23.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $269.77 – $447.03 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $389.69 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $220.3B · P/B 20.36 · P/S 5.78.
Company News
10 captured
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsightGlobenewswire Inc ·
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial DataBenzinga ·
The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?The Motley Fool ·
Should You Invest $1,000 in SCHD Right Now?The Motley Fool ·
Veeva Expands Amgen Partnership With Global Vault CRM Rollout PlanZacks Investment Research ·
Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateZacks Investment Research ·